Clinical Trial Update: Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis Patients [Phase 1]

View source ↗

Summary

Phase 1 trial comparing safety and pharmacokinetics of two SAR153191 (REGN88) drug products in patients with rheumatoid arthritis; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• SAR153191 (REGN88) Drug Product A (SAR153191)
• SAR153191 (REGN88) Drug Product B (SAR153191)

Snippet

Sponsor: Sanofi | Conditions: Rheumatoid Arthritis | Phase 1 | Status: COMPLETED